rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

The company

Bullfrog AI Holdings, Inc.

BFRG · Nasdaq

Health CareBiotechnologyNot moving yet

BFRG stood above a rising 150-day average in 0 of the last 52 weekly readings. It is 24.3% below that average now. Biotechnology: 15% of its 561 stocks in an uptrend (−17 points in four weeks); Health Care: 25% (−11 points in four weeks).

SEC filings

Statistics

Rotation
Not moving yet
Weeks in an uptrend
out for 52
Industry in uptrend
15% -17 in 4 wk
Insider buys, 12 months
$143K
Insider sales, 12 months
$0
Officials’ trades on record
0
Institutions holding
20 (+4)

In the rotation

Each square a week: lit when it closed above a rising 150-day average. 0 of 52 weeks.

17 Apr – 16 Oct
16%28%39%Apr 26Jun 26Jul 26Sep 26Oct 26

Biotechnology: Few of its stocks are in an uptrend and the share has fallen sharply over four weeks. Health Care: A minority of its stocks are in an uptrend and the share has fallen sharply over four weeks.

Money in and out

1 Nov 2024 – 1 Oct 2026
−$69K$0$135KNov 24May 25Nov 25Apr 26Oct 26

Open-market buys above the line and sales below, in dollars.

Congress and officials

No member of Congress or official has disclosed a trade in it.

Insiders

Buy orders, 12 months2
Sale orders, 12 months0
Buyers · sellers2 · 0
WhoDidSharesTraded
Vininder SinghChief Executive Officerbought75,000at $0.598922 Sep 2026filed 22 Sep 2026
Joshua BlacherChief Financial Officerbought50,000at $0.528522 Sep 2026filed 22 Sep 2026

Lines filed since 2 January 2026, newest first; every insider’s older lines are on their own page.

Institutions

Holders20+4 on the quarter
New · exited10 · 7
Reported value$939K

Quarter to 30 Jun 2026, against 31 Mar 2026; newest filing 31 Aug 2026.

ManagerSharesChange
CITADEL ADVISORS LLCnew · filed 14 Aug 2026361,546$257K+361,546
J. Safra Sarasin Holding AGunchanged · filed 31 Jul 2026113,720$191K00.0%
VANGUARD FIDUCIARY TRUST COnew · filed 13 Aug 2026106,484$76K+106,484
GEODE CAPITAL MANAGEMENT, LLCadded · filed 12 Aug 2026104,928$74K+25,068+31.4%
VANGUARD CAPITAL MANAGEMENT LLCnew · filed 13 Aug 202691,596$65K+91,596
Vontobel Holding Ltd.added · filed 3 Aug 202670,000$50K+32,000+84.2%
JANE STREET GROUP, LLCnew · filed 14 Aug 202665,980$47K+65,980
ACT Advisors, LLC.new · filed 22 Jul 202656,351$40K+56,351
FORTEM FINANCIAL GROUP, LLCunchanged · filed 20 Jul 202650,000$36K00.0%
RAYMOND JAMES FINANCIAL INCadded · filed 14 Aug 202644,411$32K+29,411+196.1%
31 Mar 2023 – 30 Jun 2026
31119Mar 23Dec 23Dec 24Sep 25Jun 26

News

No headline names it lately.

Everyone who traded it

Joshua Blacher Company insiderChief Financial Officer · last 22 Sep 20261 · 0
Vininder Singh Company insiderChief Executive Officer · last 22 Sep 20261 · 39
Jason David Hanson Company insiderDirector · last 11 Jun 20260 · 0
R. Don Elsey Company insiderDirector · last 11 Jun 20260 · 0
William Enright Company insiderDirector · last 11 Jun 20261 · 0
Dane R. Saglio Company insiderChief Financial Officer · last 18 Jan 20240 · 0

Same industry

MRNA ModernaLeading+147%
IOVA Iovance BiotherapeuticsLeading+126%
ABCL AbCellera BiologicsLeading+60%
HALO Halozyme TherapeuticsLeading+46%
XERS Xeris Biopharma HoldingsLeading+38%
ENTX Entera BioLeading+37%
HELP Helus PharmaLeading+36%
XNCR XencorLeading+30%

Distance from each stock’s own 150-day average.

Government contracts

No federal award is tied to it.

From its SEC filings

Profit per saleFY 2025 · to 31 Dec 202518.8%
Share count trendFY 2025 · to 18 Mar 202610.9%
Cash and equivalentsFY 2025 · to 31 Dec 2025$2.2M

Analyst forecasts

No analyst forecasts yet.